IPO - Bone Biologics Corp

Form Type: S-1

Filing Date: 2025-06-24

Corporate Action: Ipo

Type: New

Accession Number: 000164117225016289

Filing Summary: Bone Biologics Corporation has filed a registration statement on Form S-1 for an initial public offering of its securities. The offering includes up to 846,023 shares of common stock along with prefunded warrants and various series of warrants (Series D and Series E). The proposed public offering price is $5.91 per share, which reflects the last reported sale price on June 20, 2025, prior to the offering. The filing indicates that the shares will be sold in conjunction with warrants that enable the purchase of additional shares. A reverse stock split at a ratio of 1-for-6 was executed on June 10, 2025, which is accounted for in the share numbers presented. The offering also stipulates the opportunity for certain investors to purchase prefunded warrants to avoid exceeding beneficial ownership limits. The company intends to use the net proceeds for clinical trials and general corporate purposes. H.C. Wainwright & Co., LLC is acting as the exclusive placement agent for this offering. The transaction is expected to close on or about July 24, 2025, subject to customary closing conditions. The document contains forward-looking statements regarding the company's operations, financial conditions, and the extensive regulatory environment surrounding its products.

Form Type: DRS

Filing Date: 2025-03-17

Corporate Action: Ipo

Type: New

Accession Number: 000149315225010558

Filing Summary: Bone Biologics Corporation is planning to conduct an IPO through a draft registration statement filed confidentially with the SEC on March 17, 2025. The offering will include up to [●] shares of common stock alongside a combination of prefunded warrants and Series D and E warrants, specifically designed for an offering set to happen as soon as practicable after the registration statement is effective. The company is categorized as a smaller reporting company and aims to use the proceeds for clinical trials and general corporate purposes. This is a significant financial step for the organization, which focuses on bone regeneration technologies and needs capital for further development and regulatory approvals. The estimated public offer price and specific share count will be finalized based on market conditions at the offering time. The company reports that there will be no minimum offering requirement, and all securities will be sold together. Bone Biologics’ stock is currently listed on Nasdaq under the symbol 'BBLG.'